Regeneron Pharmaceuticals (REGN) R&D In Process (2021 - 2025)
Historic R&D In Process for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Q4 2025 value amounting to $18.7 million.
- Regeneron Pharmaceuticals' R&D In Process rose 3550.72% to $18.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $124.1 million, marking a year-over-year increase of 2287.13%. This contributed to the annual value of $124.1 million for FY2025, which is 2287.13% up from last year.
- As of Q4 2025, Regeneron Pharmaceuticals' R&D In Process stood at $18.7 million, which was up 3550.72% from $83.1 million recorded in Q3 2025.
- Regeneron Pharmaceuticals' 5-year R&D In Process high stood at $197.0 million for Q2 2022, and its period low was $7.1 million during Q1 2024.
- Its 5-year average for R&D In Process is $47.6 million, with a median of $30.0 million in 2022.
- In the last 5 years, Regeneron Pharmaceuticals' R&D In Process surged by 9964.41% in 2023 and then crashed by 8734.4% in 2024.
- Over the past 5 years, Regeneron Pharmaceuticals' R&D In Process (Quarter) stood at $48.0 million in 2021, then tumbled by 37.5% to $30.0 million in 2022, then changed by 0.0% to $30.0 million in 2023, then tumbled by 54.0% to $13.8 million in 2024, then soared by 35.51% to $18.7 million in 2025.
- Its R&D In Process stands at $18.7 million for Q4 2025, versus $83.1 million for Q3 2025 and $10.0 million for Q2 2025.